Duchenne Muscular Dystrophy Plasma
Duchenne Muscular Dystrophy Plasma - Cryopreserved plasma from IRB-consented donors with clinically confirmed DMD, a monogenic X-linked dystrophin deficiency. Suitable for muscle damage markers such as creatine kinase and myoglobin, circulating microRNA, proteomics, and pharmacodynamic endpoints for exon-skipping and gene therapy research.
Duchenne Muscular Dystrophy Plasma for Neuromuscular and Gene Therapy Research
Duchenne Muscular Dystrophy Plasma is collected from IRB-consented donors clinically diagnosed with Duchenne muscular dystrophy (DMD) and processed within one day of collection to preserve labile analytes such as muscle-derived proteins, cytokines, circulating nucleic acids, and metabolites. Cryopreserved and available in custom aliquots. Research Use Only (RUO).
Molecular Basis and Why Plasma
- DMD is an X-linked recessive monogenic disease caused by out-of-frame deletions, duplications, or point mutations in the DMD gene, resulting in absent or non-functional dystrophin.
- Dystrophin links the actin cytoskeleton to the dystrophin-associated glycoprotein complex at the sarcolemma; without it, the muscle membrane is mechanically fragile and is damaged by contraction.
- Repeated sarcolemmal injury leads to necrosis, regeneration failure, chronic inflammatory infiltration, and progressive replacement of muscle with fibrotic and adipose tissue. Cardiomyopathy and respiratory muscle weakness dominate later disease.
- Membrane leak releases intracellular muscle proteins into the circulation, which is why plasma creatine kinase and myoglobin are markedly elevated and are long-standing readouts of muscle damage.
- Muscle-enriched circulating microRNAs, sometimes called myomiRs, and cardiac markers such as natriuretic peptides and troponins are also studied in plasma as non-invasive progression measures.
- Because mutation class determines eligibility for exon-skipping and gene-directed approaches, genotype-annotated plasma is valuable for pharmacodynamic biomarker work. Plasma is acellular, so it is used for soluble analyte and circulating nucleic acid readouts rather than cell assays.
Donor Stratification Available
- DMD mutation type where documented: deletion, duplication, nonsense, or exon-skip amenable
- Age band and ambulatory status (ambulatory versus non-ambulatory)
- Corticosteroid therapy status and duration
- Disease-modifying therapy: exon-skipping antisense oligonucleotide, gene therapy, or treatment-naive
- Documented cardiac involvement and cardiac medication use
- Respiratory support status; Becker muscular dystrophy donors available separately on request
- Matched healthy controls available
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed Duchenne muscular dystrophy donors
- Processed within one day of collection
- Cryopreserved for long-term stability
- IRB-approved protocols and electronic informed consent, with parental or guardian permission for minors
- Custom aliquot volumes available upon request
De-identified Donor Data
- Verified Duchenne muscular dystrophy diagnosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Genotype, ambulatory status, and cardiac history where available
- Additional DMD-specific metadata available on request
Applications
- Muscle damage biomarker measurement, including creatine kinase and myoglobin
- Circulating microRNA and cell-free nucleic acid profiling
- Plasma proteomics for progression and severity biomarkers
- Cardiac biomarker research in DMD-associated cardiomyopathy
- Metabolomic analysis of muscle energetics and wasting
- Cytokine and fibrosis-related mediator profiling
- Pharmacodynamic endpoints for exon-skipping and gene therapy programs
- Genotype-stratified assay development and validation
Other Duchenne Muscular Dystrophy Specimen Types
- Duchenne Muscular Dystrophy Serum
- Duchenne Muscular Dystrophy Whole Blood
- Duchenne Muscular Dystrophy PBMC
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Duchenne Muscular Dystrophy Plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse all matrices and disease states, visit our human plasma page.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.